Table of Contents
Breaking Insights
Reviews
- ReviewsLevon M. KhachigianCancer Res March 1 2019 79 (5) 879-888; DOI:10.1158/0008-5472.CAN-18-2474
- ReviewsErica W. Cloer, Dennis Goldfarb, Travis P. Schrank, Bernard E. Weissman and Michael B. MajorCancer Res March 1 2019 79 (5) 889-898; DOI:10.1158/0008-5472.CAN-18-2723
Priority Report
- Priority ReportElin M.V. Forsberg, Mattias F. Lindberg, Henrik Jespersen, Samuel Alsén, Roger Olofsson Bagge, Marco Donia, Inge Marie Svane, Ola Nilsson, Lars Ny, Lisa M. Nilsson and Jonas A. NilssonCancer Res March 1 2019 79 (5) 899-904; DOI:10.1158/0008-5472.CAN-18-3158
These findings demonstrate that a novel humanized mouse model can help clinical translation of CAR-T cells against uveal and cutaneous melanoma that do not respond to TIL therapy or immune checkpoint blockade.
Genome and Epigenome
- Genome and Epigenome | AuthorChoicePauline J. Beckmann, Jon D. Larson, Alex T. Larsson, Jason P. Ostergaard, Sandra Wagner, Eric P. Rahrmann, Ghaidan A. Shamsan, George M. Otto, Rory L. Williams, Jun Wang, Catherine Lee, Barbara R. Tschida, Paramita Das, Adrian M. Dubuc, Branden S. Moriarity, Daniel Picard, Xiaochong Wu, Fausto J. Rodriguez, Quincy Rosemarie, Ryan D. Krebs, Amy M. Molan, Addison M. Demer, Michelle M. Frees, Anthony E. Rizzardi, Stephen C. Schmechel, Charles G. Eberhart, Robert B. Jenkins, Robert J. Wechsler-Reya, David J. Odde, Annie Huang, Michael D. Taylor, Aaron L. Sarver and David A. LargaespadaCancer Res March 1 2019 79 (5) 905-917; DOI:10.1158/0008-5472.CAN-18-1261
A transposon-induced mouse model identifies several novel genetic drivers and potential therapeutic targets in medulloblastoma and CNS-PNET.
- Genome and EpigenomePraveen Rajendran, Gavin Johnson, Li Li, Ying-Shiuan Chen, Mohaiza Dashwood, Nhung Nguyen, Ahmet Ulusan, Furkan Ertem, Mutian Zhang, Jia Li, Deqiang Sun, Yun Huang, Shan Wang, Hon-Chiu Leung, David Lieberman, Laura Beaver, Emily Ho, Mark Bedford, Kyle Chang, Eduardo Vilar and Roderick DashwoodCancer Res March 1 2019 79 (5) 918-927; DOI:10.1158/0008-5472.CAN-18-2003
These results highlight the competition that exists among the “readers” of acetylated histone and nonhistone proteins and provide a mechanistic basis for potential new therapeutic avenues involving epigenetic combination treatments.
Molecular Cell Biology
- Molecular Cell BiologyCheng Zhang, Like Qu, Shenyi Lian, Lin Meng, Li Min, Jiafei Liu, Qian Song, Lin Shen and Chengchao ShouCancer Res March 1 2019 79 (5) 928-940; DOI:10.1158/0008-5472.CAN-18-0520
Dephosphorylation of FZR1 by PRL-3 facilitates the activity of APC/CFZR1 by destabilizing AURKA, thus influencing aggressive characteristics and overall progression of colorectal cancer.
- Molecular Cell BiologyYuanzhuo Gu, Xiyang Wei, Yulin Sun, Hongjun Gao, Xin Zheng, Linda L. Wong, Ling Jin, Niya Liu, Brenda Hernandez, Karolina Peplowska, Xiaohang Zhao, Qi-Min Zhan, Xin-Hua Feng, Zhao-You Tang and Junfang JiCancer Res March 1 2019 79 (5) 941-953; DOI:10.1158/0008-5472.CAN-18-1675
miR-192-5p and its regulatory pathway is significantly abolished in multiple groups of HCC expressing high levels of CSC markers, which may represent a key event for hepatic carcinogenesis.
- Molecular Cell BiologyYi Liu, Yasunori Deguchi, Rui Tian, Daoyan Wei, Ling Wu, Weidong Chen, Weiguo Xu, Min Xu, Fuyao Liu, Shen Gao, Jonathan C. Jaoude, Sarah P. Chrieki, Micheline J. Moussalli, Mihai Gagea, Jeffrey Morris, Russell R. Broaddus, Xiangsheng Zuo and Imad ShureiqiCancer Res March 1 2019 79 (5) 954-969; DOI:10.1158/0008-5472.CAN-18-1790
These findings address long-standing, important, and unresolved questions related to the potential role of PPARD in APC mutation-dependent colorectal tumorigenesis by showing PPARD activation enhances APC mutation-dependent tumorigenesis.
Tumor Biology and Immunology
- Tumor Biology and ImmunologyDustin J. Flanagan, Nick Barker, Natasha S. Di Costanzo, Elizabeth A. Mason, Austin Gurney, Valerie S. Meniel, Sarah Koushyar, Chloe R. Austin, Matthias Ernst, Helen B. Pearson, Alex Boussioutas, Hans Clevers, Toby J. Phesse and Elizabeth VincanCancer Res March 1 2019 79 (5) 970-981; DOI:10.1158/0008-5472.CAN-18-2095
The Wnt receptor Fzd7 plays an essential role in gastric tumorigenesis irrespective of Apc mutation status, therefore targeting Wnt/Fzd7 may be of therapeutic benefit to patients with gastric cancer.
Translational Science
- Translational ScienceIkbale El Ayachi, Iram Fatima, Peter Wend, Jackelyn A. Alva-Ornelas, Stephanie Runke, William L. Kuenzinger, Julio Silva, Wendy Silva, Joseph K. Gray, Stephan Lehr, Hilaire C. Barch, Raisa I. Krutilina, Andrew C. White, Robert Cardiff, Lisa D. Yee, Lily Yang, Ruth M. O'Regan, William E. Lowry, Tiffany N. Seagroves, Victoria Seewaldt, Susan A. Krum and Gustavo A. Miranda-CarboniCancer Res March 1 2019 79 (5) 982-993; DOI:10.1158/0008-5472.CAN-18-1069
These findings reveal targeting the WNT signaling pathway as a potential therapeutic strategy in triple-negative breast cancer.
- Translational ScienceMatthew L. Hemming, Matthew A. Lawlor, Jessica L. Andersen, Timothy Hagan, Otari Chipashvili, Thomas G. Scott, Chandrajit P. Raut, Ewa Sicinska, Scott A. Armstrong, George D. Demetri and James E. BradnerCancer Res March 1 2019 79 (5) 994-1009; DOI:10.1158/0008-5472.CAN-18-1888
Expression and activity of mutant KIT is essential for driving the majority of GIST neoplasms, which can be therapeutically targeted using BET bromodomain inhibitors.
Resource Report
- Resource ReportDarlan Conterno Minussi, Bernardo Henz, Mariana dos Santos Oliveira, Eduardo C. Filippi-Chiela, Manuel M. Oliveira and Guido LenzCancer Res March 1 2019 79 (5) 1010-1013; DOI:10.1158/0008-5472.CAN-17-3924
This study provides a customizable and hands-on simulation tool to model the effect of diverse types of genomic alterations on the fate of tumor cells.
Corrections
- Corrections | Free ArticleAkshata R. Udyavar, David J. Wooten, Megan Hoeksema, Mukesh Bansal, Andrea Califano, Lourdes Estrada, Santiago Schnell, Jonathan M. Irish, Pierre P. Massion and Vito QuarantaCancer Res March 1 2019 79 (5) 1014-1014; DOI:10.1158/0008-5472.CAN-19-0069
- Corrections | Free ArticleShasha Tao, Shue Wang, Seyed Javad Moghaddam, Aikseng Ooi, Eli Chapman, Pak K. Wong and Donna D. ZhangCancer Res March 1 2019 79 (5) 1015-1015; DOI:10.1158/0008-5472.CAN-19-0070
Retraction
- Retraction | Free ArticleSudhakar Ammanamanchi, Manoranjani P.M. Tillekeratne, Tien C. Ko and Michael G. BrattainCancer Res March 1 2019 79 (5) 1016-1016; DOI:10.1158/0008-5472.CAN-19-0071
Volume 79, Issue 5